AskBio Inc — Biomedical Watch V2

Traitements3programmes

Essais1liés

Publications5liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
AB-1003 dose level 1The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)	Myopathies	Phase 1/2	À vérifier	United States	À vérifier
AB-1003 dose level 2The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)	Myopathies	Phase 1/2	À vérifier	United States	À vérifier
AB-1003 dose level 1The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)	Myopathies	Phase 1/2	À vérifier	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
AB-1003 dose level 1	Myopathies	Phase 1/2	NCT05230459	A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)	ACTIVE_NOT_RECRUITING

Publications

5

Molécule	Indication / population	Titre	Journal	Date
AB-1003 dose level 2		Assessment of Xiao'er Xiexieting Keli-induced toxicity in juvenile rats.	Journal of ethnopharmacology
AB-1003 dose level 1		In vivo antimalarial activity and acute toxicity of organic and aqueous leaf, stem and root extracts of Ajuga integrifolia Buch.-Ham. ex D. Don.	Journal of ethnopharmacology
AB-1003 dose level 2		Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta-analysis.	British journal of clinical pharmacology
AB-1003 dose level 1		Hyperkalemia Risk After Finerenone Initiation in Diabetic Kidney Disease with Elevated Baseline Potassium: A Multicenter Cohort Study.	Journal of clinical medicine
AB-1003 dose level 1		Anticoagulation Stewardship in the Era of Practice-Changing Evidence: A Narrative Review of Recent Trials and Their Bedside Translation.	Journal of clinical medicine